Just The Facts: Orthocell Achieves Fda Study Milestone For Remplir Nerve Repair Product

Just the Facts: Orthocell achieves FDA study milestone for Remplir™ nerve repair product

Proactive Investors

Orthocell Breakthrough: FDA Study Validates Remplir™ for Nerve Repair Surgery

Orthocell prepares Remplir™ for US market with new executives

Proactive Investors

Remplir - Nerve repair

Orthocell achieves record growth with Striate+ and Remplir

Proactive Investors

Orthocell delivers outstanding results in Remplir™ nerve regeneration trial

Proactive Investors

Orthocell expands Remplir™ sales to Singapore

Proactive Investors

Orthocell hits record revenue thanks to Striate+™ and Remplir™ products

Proactive Investors

Education in autonomic medicine in Europe

An umbrella review of early mobilization decision after acute stroke

Orthocell talks appointment of exclusive Australian distributor for Remplir™

Proactive Investors

Advance care planning in epilepsy

What defines a successful epilepsy surgery?

What’s new in ESO guidelines?

Patent foramen ovale: the unresolved questions

Can I Get a Deferral if I Miss GMC Revalidation Requirements? ❓ | Medical Appraiser

Medical Appraisals

Simplifying the assessment of central vein sign positivity in clinical practice

New guidelines on the diagnosis and management of PFO after stroke

Atrial fibrillation after a stroke and the concept of AFDAS